Clinical Trial Update: A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BL-B01D1 in combination with Almonertinib for resectable EGFR-positive stage II-IIIB non-small cell lung cancer; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)
• BL-B01D1

Snippet

Sponsor: Sichuan University | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING